S&P 500   4,140.06 (-0.12%)
DOW   32,832.54 (+0.09%)
QQQ   320.71 (-0.32%)
AAPL   164.87 (-0.29%)
MSFT   280.32 (-0.92%)
META   170.25 (+1.88%)
GOOGL   117.30 (-0.14%)
AMZN   139.41 (-0.99%)
TSLA   871.27 (+0.78%)
NVDA   177.93 (-6.30%)
NIO   20.17 (-0.25%)
BABA   90.84 (-1.86%)
AMD   100.07 (-2.19%)
MU   61.45 (-1.62%)
T   18.00 (-1.91%)
CGC   3.28 (+21.48%)
GE   75.18 (+1.10%)
F   15.78 (+3.14%)
DIS   109.11 (+2.33%)
AMC   23.96 (+8.03%)
PYPL   96.26 (+0.99%)
PFE   49.57 (+0.61%)
NFLX   233.49 (+2.96%)
S&P 500   4,140.06 (-0.12%)
DOW   32,832.54 (+0.09%)
QQQ   320.71 (-0.32%)
AAPL   164.87 (-0.29%)
MSFT   280.32 (-0.92%)
META   170.25 (+1.88%)
GOOGL   117.30 (-0.14%)
AMZN   139.41 (-0.99%)
TSLA   871.27 (+0.78%)
NVDA   177.93 (-6.30%)
NIO   20.17 (-0.25%)
BABA   90.84 (-1.86%)
AMD   100.07 (-2.19%)
MU   61.45 (-1.62%)
T   18.00 (-1.91%)
CGC   3.28 (+21.48%)
GE   75.18 (+1.10%)
F   15.78 (+3.14%)
DIS   109.11 (+2.33%)
AMC   23.96 (+8.03%)
PYPL   96.26 (+0.99%)
PFE   49.57 (+0.61%)
NFLX   233.49 (+2.96%)
S&P 500   4,140.06 (-0.12%)
DOW   32,832.54 (+0.09%)
QQQ   320.71 (-0.32%)
AAPL   164.87 (-0.29%)
MSFT   280.32 (-0.92%)
META   170.25 (+1.88%)
GOOGL   117.30 (-0.14%)
AMZN   139.41 (-0.99%)
TSLA   871.27 (+0.78%)
NVDA   177.93 (-6.30%)
NIO   20.17 (-0.25%)
BABA   90.84 (-1.86%)
AMD   100.07 (-2.19%)
MU   61.45 (-1.62%)
T   18.00 (-1.91%)
CGC   3.28 (+21.48%)
GE   75.18 (+1.10%)
F   15.78 (+3.14%)
DIS   109.11 (+2.33%)
AMC   23.96 (+8.03%)
PYPL   96.26 (+0.99%)
PFE   49.57 (+0.61%)
NFLX   233.49 (+2.96%)
S&P 500   4,140.06 (-0.12%)
DOW   32,832.54 (+0.09%)
QQQ   320.71 (-0.32%)
AAPL   164.87 (-0.29%)
MSFT   280.32 (-0.92%)
META   170.25 (+1.88%)
GOOGL   117.30 (-0.14%)
AMZN   139.41 (-0.99%)
TSLA   871.27 (+0.78%)
NVDA   177.93 (-6.30%)
NIO   20.17 (-0.25%)
BABA   90.84 (-1.86%)
AMD   100.07 (-2.19%)
MU   61.45 (-1.62%)
T   18.00 (-1.91%)
CGC   3.28 (+21.48%)
GE   75.18 (+1.10%)
F   15.78 (+3.14%)
DIS   109.11 (+2.33%)
AMC   23.96 (+8.03%)
PYPL   96.26 (+0.99%)
PFE   49.57 (+0.61%)
NFLX   233.49 (+2.96%)
NASDAQ:MEDP

Medpace - MEDP Stock Forecast, Price & News

$168.69
+3.03 (+1.83%)
(As of 08/8/2022 05:24 PM ET)
Add
Compare
Today's Range
$166.57
$171.51
50-Day Range
$132.27
$169.53
52-Week Range
$126.94
$231.00
Volume
322,804 shs
Average Volume
344,085 shs
Market Capitalization
$5.23 billion
P/E Ratio
29.29
Dividend Yield
N/A
Price Target
$175.00

Medpace MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
3.6% Upside
$175.00 Price Target
Short Interest
Bearish
7.84% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.62
Upright™ Environmental Score
News Sentiment
0.42mentions of Medpace in the last 14 days
Based on 14 Articles This Week
Insider Trading
Acquiring Shares
$4.43 M Bought Last Quarter
Proj. Earnings Growth
5.68%
From $6.16 to $6.51 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.04 out of 5 stars

Medical Sector

647th out of 1,293 stocks

Commercial Physical Research Industry

12th out of 20 stocks

MEDP stock logo

About Medpace (NASDAQ:MEDP) Stock

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio.

Medpace Stock Performance

Shares of MEDP Stock opened at $165.66 on Monday. Medpace has a 52-week low of $126.94 and a 52-week high of $231.00. The stock has a market cap of $5.14 billion, a price-to-earnings ratio of 28.76 and a beta of 1.43. The firm has a fifty day moving average of $151.26 and a 200-day moving average of $152.32.

Medpace (NASDAQ:MEDP - Get Rating) last posted its earnings results on Monday, July 25th. The company reported $1.46 earnings per share for the quarter, topping the consensus estimate of $1.33 by $0.13. Medpace had a net margin of 16.27% and a return on equity of 30.56%. The business had revenue of $351.21 million for the quarter, compared to analyst estimates of $344.01 million. During the same quarter in the prior year, the firm earned $1.06 EPS. The firm's quarterly revenue was up 26.2% compared to the same quarter last year. On average, sell-side analysts predict that Medpace will post 6.16 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Guggenheim assumed coverage on shares of Medpace in a research note on Monday, May 23rd. They issued a "neutral" rating for the company. StockNews.com upgraded shares of Medpace from a "hold" rating to a "buy" rating in a research note on Thursday, July 28th.

Insiders Place Their Bets

In related news, CEO August J. Troendle acquired 8,330 shares of the firm's stock in a transaction on Monday, July 18th. The shares were purchased at an average price of $145.00 per share, with a total value of $1,207,850.00. Following the acquisition, the chief executive officer now directly owns 5,513,639 shares in the company, valued at $799,477,655. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, CEO August J. Troendle purchased 22,290 shares of the business's stock in a transaction that occurred on Thursday, July 14th. The shares were acquired at an average cost of $144.59 per share, for a total transaction of $3,222,911.10. Following the transaction, the chief executive officer now directly owns 5,505,309 shares of the company's stock, valued at approximately $796,012,628.31. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO August J. Troendle purchased 8,330 shares of the business's stock in a transaction that occurred on Monday, July 18th. The stock was purchased at an average price of $145.00 per share, for a total transaction of $1,207,850.00. Following the completion of the transaction, the chief executive officer now directly owns 5,513,639 shares in the company, valued at $799,477,655. The disclosure for this purchase can be found here. Insiders own 20.60% of the company's stock.

Receive MEDP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medpace and its competitors with MarketBeat's FREE daily newsletter.

MEDP Stock News Headlines

3 Reasons Growth Investors Will Love Medpace (MEDP)
See More Headlines
Receive MEDP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medpace and its competitors with MarketBeat's FREE daily newsletter.

MEDP Company Calendar

Last Earnings
7/25/2022
Today
8/08/2022
Next Earnings (Estimated)
10/24/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Commercial physical research
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MEDP
Employees
4,500
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$175.00
High Stock Price Forecast
$175.00
Low Stock Price Forecast
$175.00
Forecasted Upside/Downside
+3.7%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

Net Income
$181.85 million
Pretax Margin
18.50%

Debt

Sales & Book Value

Annual Sales
$1.14 billion
Cash Flow
$5.73 per share
Book Value
$26.51 per share

Miscellaneous

Free Float
24,613,000
Market Cap
$5.23 billion
Optionable
Optionable
Beta
1.43














MEDP Stock - Frequently Asked Questions

Should I buy or sell Medpace stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medpace in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" MEDP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MEDP, but not buy additional shares or sell existing shares.
View MEDP analyst ratings
or view top-rated stocks.

What is Medpace's stock price forecast for 2022?

1 analysts have issued 12 month target prices for Medpace's stock. Their MEDP stock forecasts range from $175.00 to $175.00. On average, they expect the company's share price to reach $175.00 in the next twelve months. This suggests a possible upside of 3.2% from the stock's current price.
View analysts price targets for MEDP
or view top-rated stocks among Wall Street analysts.

How has Medpace's stock price performed in 2022?

Medpace's stock was trading at $217.64 at the beginning of the year. Since then, MEDP shares have decreased by 22.1% and is now trading at $169.60.
View the best growth stocks for 2022 here
.

When is Medpace's next earnings date?

Medpace is scheduled to release its next quarterly earnings announcement on Monday, October 24th 2022.
View our MEDP earnings forecast
.

How were Medpace's earnings last quarter?

Medpace Holdings, Inc. (NASDAQ:MEDP) issued its quarterly earnings data on Monday, July, 25th. The company reported $1.46 earnings per share for the quarter, topping the consensus estimate of $1.33 by $0.13. The company had revenue of $351.21 million for the quarter, compared to the consensus estimate of $344.01 million. Medpace had a net margin of 16.27% and a trailing twelve-month return on equity of 30.56%. The business's quarterly revenue was up 26.2% compared to the same quarter last year. During the same period in the prior year, the company earned $1.06 EPS.

What guidance has Medpace issued on next quarter's earnings?

Medpace issued an update on its FY 2022 earnings guidance on Monday, August, 1st. The company provided EPS guidance of $6.07-$6.36 for the period, compared to the consensus EPS estimate of $5.82. The company issued revenue guidance of $1.41 billion-$1.44 billion, compared to the consensus revenue estimate of $1.40 billion.

What is August Troendle's approval rating as Medpace's CEO?

268 employees have rated Medpace Chief Executive Officer August Troendle on Glassdoor.com. August Troendle has an approval rating of 34% among the company's employees. This puts August Troendle in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Medpace own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Medpace investors own include NVIDIA (NVDA), Exact Sciences (EXAS), Block (SQ), Baidu (BIDU), JD.com (JD), Advanced Micro Devices (AMD), Bilibili (BILI), Alibaba Group (BABA), Cisco Systems (CSCO) and Intuitive Surgical (ISRG).

When did Medpace IPO?

(MEDP) raised $150 million in an IPO on Thursday, August 11th 2016. The company issued 7,000,000 shares at $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities served as the underwriters for the IPO and Baird and William Blair were co-managers.

What is Medpace's stock symbol?

Medpace trades on the NASDAQ under the ticker symbol "MEDP."

Who are Medpace's major shareholders?

Medpace's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Boston Trust Walden Corp (2.05%), Riverbridge Partners LLC (1.43%), TD Asset Management Inc. (0.86%), Loomis Sayles & Co. L P (0.78%), Redwood Investments LLC (0.33%) and Congress Asset Management Co. MA (0.34%). Insiders that own company stock include Ashley M Keating, August J Troendle, August J Troendle, Jesse J Geiger, Kevin M Brady, Medpace Investors, Llc, Peter J O'malley, Stephen P Ewald, Stephen P Ewald, Susan E Burwig, Tom C King and Wedbush Securities Inc.
View institutional ownership trends
.

How do I buy shares of Medpace?

Shares of MEDP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Medpace's stock price today?

One share of MEDP stock can currently be purchased for approximately $169.60.

How much money does Medpace make?

Medpace (NASDAQ:MEDP) has a market capitalization of $5.26 billion and generates $1.14 billion in revenue each year. The company earns $181.85 million in net income (profit) each year or $5.76 on an earnings per share basis.

How many employees does Medpace have?

Medpace employs 4,500 workers across the globe.

How can I contact Medpace?

Medpace's mailing address is 5375 MEDPACE WAY, CINCINNATI OH, 45227. The official website for the company is www.medpace.com. The company can be reached via phone at (513) 579-9911, via email at investor@medpace.com, or via fax at 513-579-0444.

This page (NASDAQ:MEDP) was last updated on 8/8/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.